Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
COLORADO SPRINGS, Colo., Dec. 28, 2016 -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the 35th Annual J.P. Morgan Healthcare Conference on January 11, 2017 in San Francisco, California. The presentation is scheduled for 3:30 pm PT. A live audio webcast of the presentation will be available on the Investor Relations portion of Spectranetics’ website at http://www.spectranetics.com/investor-relations/investor-events/.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen [email protected] (719) 447-2292 Michaella Gallina [email protected] (719) 447-2417
